

# Tillotts Pharma Transfers of Value in 2019 to Turkish Healthcare Professionals and Healthcare Organisations

Date of publication: June 2020

	Full Name  (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered  (Art. 3)	Country of Principal Practice  (Schedule 1)	Principal Practice Address  (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)			
						Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the contract, including travel & accommodation relevant to the contract		
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A	31'789 TRY	82'486 TRY			
	Number of Recipients in aggregate disclosure					N/A	N/A	20	20			
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					N/A	N/A	100%	100%			
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients											
	Number of Recipients in aggregate disclosure											
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02											
R & D	AGGREGATE DISCLOSURE											
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											

## **Methodological Notes**

### **Disclosure by Tillotts Pharma of payments to Turkish healthcare professionals and healthcare organisations in 2019**

The European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code mandates the public disclosure in 2020 of certain transfers of value made during 2019 to European healthcare professionals and healthcare organisations. Tillotts Pharma is publishing such transfers of value made in 2019 to Turkish healthcare professionals and Turkish healthcare organisations on the website of Tillotts Pharma, [www.tillotts.com](http://www.tillotts.com), consistent with the EFPIA Disclosure Code.

The methodological notes below explain the data Tillotts Pharma have disclosed and how the data have been prepared, to assist the reader's understanding.

#### **VAT**

VAT is excluded from all disclosures of transfer of value.

#### **Currency**

All disclosures are made in Turkish Lira (TRY). Where the original payment was made in another currency, the sum was converted to Lira at 2019 annual average exchange rate.

#### **Consolidated Disclosures of the Corporate Group and Cross-border Payments**

The disclosures represent the consolidated transfers of value made by the Tillotts Pharma corporate group in line with the EFPIA Disclosure Code's dictate that separate entities belonging to the same multinational company (which could be the parent company and subsidiary company) shall be deemed to constitute a single company. In 2019, all transfers of value represent payments made by Tillotts Pharma AG.

#### **Multi-year contracts**

Where multi-year contracts are included in the disclosure of transfer of value made by Tillotts Pharma in 2019, the disclosures related to these multi-year contracts represent the payments made in calendar year 2019 under such contracts.

#### **Data included**

The data disclosed by Tillotts Pharma is consistent with the requirements of the EFPIA Disclosure Code. The data can be categorised as follows:

##### *Sponsorship of healthcare professionals to attend educational events*

Disclosed data includes all travel costs, such as flights, transfers from airport to hotel or congress venue, train and underground/metro journeys. The disclosure data also includes accommodation costs such as hotel rooms, but does not include food and drink costs. The disclosure data also includes the registration fee, where applicable, for the healthcare professional to be registered to attend the educational event.